Navigation Links
Trading Halted Today in Questcor Pharmaceuticals Common Stock

UNION CITY, Calif., May 6 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that NASDAQ has halted trading of Questcor's common stock pending news. The Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review and discuss the Company's supplemental New Drug Application (sNDA) to market H.P. Acthar® Gel (repository corticotrophin injection) for the treatment of infantile spasms.

Conference Call on Monday, May 10, 2010

Questcor will host a conference call and webcast to discuss the results of the FDA Panel meeting on Monday, May 10, 2010 at 4:30 p.m. Eastern / 1:30 p.m. Pacific. Don Bailey, President and Chief Executive Officer; Steve Cartt, Executive Vice President & Chief Business Officer; Dr. David Young, Chief Science Officer; and Dr. Jason Zielonka, Senior Vice President and Chief Medical Officer will participate. The dial-in number for the conference call is 877-941-9205 for domestic participants and 480-629-9835 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4292117#. To access the live webcast of the call, go to Questcor Pharmaceuticals' website at An archived webcast will also be available at

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar® Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MyPunchbowl Inks Deal with Oriental Trading Company
2. ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today
3. Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol UNIS
4. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
5. KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
6. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
7. Rx for Africa, Inc. Now Trading Under New Symbol (RXAF.PK)
8. Physicians Foundation Warns of Potential Impact From New Medicare Cuts Effective Today
9. Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
10. Elsevier is Meeting Todays Medical Students Needs With Online, Mobile and Print Tools
11. HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today
Post Your Comments:
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis ... global supply chains, has published the first annual edition of its Global ... more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that ... ... Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... named one of Michigan’s 2017 Best and Brightest in Wellness® by Best and ... Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. ...
Breaking Medicine News(10 mins):